Dementia and Alzheimer Disease

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 7, 2022.

When hydromethylthionine mesylate was compared with publicly available placebo decline data, the treatment effects of cognitive and functional decline are about 3-fold larger over 18 months.

Expert clinicians offer their perspectives on developmental milestones for children, the NMSOD patient perspective, effective treatments for insomnia, ALS, diabetic and inflammatory neuropathies, and lecanemab in early Alzheimer disease.

In 2 phase 3 randomized placebo-controlled trials, findings showed that although crenezumab was well tolerated, it did not reduce clinical decline in participants with early Alzheimer disease.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

With diagnosis rates of Alzheimer disease increasing, Tabby Khan, MD, MPH, spoke to the need to focus on cognitive decline in younger patient populations.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology, related to the recent 4th Annual International Congress on the Future of Neurology®.

Neurology News Network for the week ending October 1, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 23, 2022.

The neurologist and assistant professor at the University of Toronto discussed the real, but tepid significance of amyloid-related imaging abnormalities seen from lecanemab in early-stage Alzheimer disease. [WATCH TIME: 3 minutes]

The neurologist and assistant professor at the University of Toronto provided insight on positive topline findings from the phase 3 Clarity AD study of lecanemab in early Alzheimer disease. [WATCH TIME: 4 minutes]

The investigational treatment from Eisai and Biogen significantly reduced the Clinical Dementia Rating-Sum of Boxes scores among patients with early AD, with safety and ARIA-E and ARIA-H incidence as expected.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 23, 2022.

The director of NYU Langone’s Alzheimer’s Disease Research Center and Center for Cognitive Neurology provided perspective on raising awareness for World Alzheimer’s Day and the ongoing challenges patients with the disease face.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

Neurology News Network for the week ending September 17, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 16, 2022.

Patients who demonstrated increased central pulse pressure and forward wave amplitude had greater entorhinal tau burden. These measures were not associated with amygdala, inferior temporal, nor precuneus tau burden.

Long-term use of the Constant Therapy program was feasible in a patient population with Alzheimer disease, as shown by the rate of adherence (80%) and use of the program over 24 weeks.

The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed the unanswered questions regarding biomarkers sTREM2 and GFAP, and the role they play in Alzheimer pathology.

In a previous phase 2 study, patients treated with fosgonimeton alone demonstrated potentially beneficial change in ERP P300 latency, as well as cognitive improvement, compared with placebo at 26 weeks.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 9, 2022.

Using patients with post–COVID-19 neurological symptoms, 90% of the cohort fulfilled the criteria for chronic fatigue syndrome, as expressed by the SOFA scale.

The molecular biologist at the Cleveland Clinic Lerner Research Institute provided commentary on how certain activity markers may help understand immune response differences in Alzheimer disease and related dementias.